ZLDAF (Zelira Therapeutics) Research & Development: $1.71 Mil (TTM As of Jun. 2025)


ZLDAF Zelira Therapeutics Ltd ZLDAF
10 GF Score
Price $0.35
GF Value $0.08
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Zelira Therapeutics Research & Development?

Zelira Therapeutics ZLDAF 10 Research & Development is $1.71 Mil as of Jun. 2025. GuruFocus rates ZLDAF with a GF Score™ of 10/100 and a GF Value™ of $0.08 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Zelira Therapeutics's Research & Development for the six months ended in Jun. 2025 was $0.82 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2025 was $1.71 Mil.

Zelira Therapeutics  (OTCPK:ZLDAF) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Zelira Therapeutics Research & Development Related Terms

Zelira Therapeutics Research & Development Historical Data

* Premium members only.

The historical data trend for Zelira Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zelira Therapeutics Research & Development Chart

Zelira Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.59 0.00 0.90 1.87 1.74

Zelira Therapeutics Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.53 0.83 1.04 0.89 0.82
ZLDAF
10GF Score
Zelira Therapeutics Ltd ZLDAF
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zelira Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $1.71 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $1.71 Mil mean?
Zelira Therapeutics (ZLDAF) has a Research & Development of $1.71 Mil as of Jun. 2025. Research and development expense is the total cost for research and development activities. View historical data on Zelira Therapeutics and its competitors.
Is Zelira Therapeutics' Research & Development too high?
Zelira Therapeutics' current Research & Development is $1.71 Mil. Overall, Zelira Therapeutics has a GF Score™ of 10/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Zelira Therapeutics' Research & Development compare to MTNB and SXTP?
Zelira Therapeutics' Research & Development of $1.71 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Zelira Therapeutics and its competitors. Zelira Therapeutics's current Research & Development is $1.71 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zelira Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Zelira Therapeutics (ZLDAF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.08, compared to a current price of $0.35 — trading 337.5% above its estimated fair value. The current Research & Development is $1.71 Mil. Zelira Therapeutics' overall GF Score™ is 10/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Zelira Therapeutics (ZLDAF), the current Research & Development is $1.71 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zelira Therapeutics (ZLDAF) Overvalued in 2026?

Based on GuruFocus' analysis, Zelira Therapeutics stock appears to be overvalued. The current stock price of $0.35 is trading 337.5% above its estimated GF Value™ of $0.08. GuruFocus considers Zelira Therapeutics to be Significantly Overvalued.

Key valuation signals for ZLDAF:

  • Research & Development: $1.71 Mil
  • GF Value™: $0.08 vs. price of $0.35 (337.5% above fair value)
  • GF Score™: 10/100 with 7 warning signs

No single metric tells the full story. See the ZLDAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zelira Therapeutics Business Description

Address 101 St George’s Terrace, Level 3, Perth, WA, AUS, 6000
Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema, and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer. The company is organised into two operating segments based on geographic location of operations: Australia and United States of America.
10GF Score

Get the complete analysis for ZLDAF

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.35
Price
$0.08
GF Value